The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Metformin Hydrochloride, effective 2026-08-11. This significant update specifically addresses the risks of metformin-associated lactic acidosis. The revision highlights that postmarketing cases of this serious condition have led to severe outcomes, including death, hypothermia, hypotension, and resistant bradyarrhythmias. The updated warning also emphasizes that the onset of metformin-associated lactic acidosis is often subtle, making early detection challenging.
Background
The label revision pertains to Metformin Hydrochloride, a drug also found in combination formulations such as those containing canagliflozin (e.g., Invokamet, Invokamet XR). Other related drugs include dapagliflozin and empagliflozin.
Key results
The revised boxed warning for Metformin Hydrochloride highlights the risk of lactic acidosis. It states that postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The warning also notes that the onset of metformin-associated lactic acidosis is often subtle.
What this means
The revision to the Metformin Hydrochloride boxed warning serves as a critical update for healthcare professionals, underscoring the continued importance of vigilance for lactic acidosis in patients. Clinicians should be acutely aware of the specific severe outcomes, such as death and resistant bradyarrhythmias, and the potentially subtle presentation of this adverse event, as detailed in the updated label. This information is crucial for enhancing patient monitoring, improving risk assessment, and guiding appropriate management strategies for patients receiving metformin-containing medications.
Source
This information is based on an FDA label revision for Metformin Hydrochloride, effective 2026-08-11. The source document is available on dailymed.nlm.nih.gov.